The effects of cisapride on plasma L‐dopa levels and clinical response in Parkinson's disease
Identifieur interne : 001D99 ( Istex/Corpus ); précédent : 001D98; suivant : 001E00The effects of cisapride on plasma L‐dopa levels and clinical response in Parkinson's disease
Auteurs : Walter Diaz Neira ; Vicenta Sanchez ; Maria Angeles Mena ; de YebenesSource :
- Movement Disorders [ 0885-3185 ] ; 1995-01.
English descriptors
- KwdEn :
Abstract
Cisapride (CIS) is a prokinetic agent that increases gastrointestinal motility in normal individuals and improves constipation in Parkinson's disease (PD). We studied the effects of CIS on the clinical response and the peripheral pharmacokinetics of orally administered L‐dopa given to patients with PD. Twenty patients with idiopathic PD and chronic constipation, whose response to L‐dopa was suboptimal or characterized by fluctuations, agreed to participate in an open study that lasted for 2 weeks. Fourteen patients completed the study (mean age 65 ± 9.3 years, mean duration of treatment 5.7 ± 4.2 years, mean L‐dopa daily doses 658.9 ± 269.9 mg); six patients were excluded due to lack of compliance or changes in medication during the study. The end points of the study included the mean levels of L‐dopa, the height of the peak of L‐dopa in plasma, mean plasma levels of 3‐OM‐dopa, and the speed and quality of gait and visuomanual corrdination before and during treatment with CIS. CIS increased peak plasma levels of L‐dopa by 37% and the mean plasma levels of L‐dopa by 13% with respect to those obtained with the same dose of L‐dopa before the addition of CIS. Therefor, CIS appears to increase early absorption of L‐dopa through acceleration of gastric emptying. CIS also increased plasma 3‐OM‐dopa levels, improved visuomanual coordination, and reduced gait disability. CIS improves gastrointestinal function and response to L‐dopa in patients with PD and could be a helpful add‐on medication in these patients.
Url:
DOI: 10.1002/mds.870100111
Links to Exploration step
ISTEX:58E04CD2695E5BBF9B482C9A1EFF6425DAAB4730Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The effects of cisapride on plasma L‐dopa levels and clinical response in Parkinson's disease</title><author><name sortKey="Neira, Walter Diaz" sort="Neira, Walter Diaz" uniqKey="Neira W" first="Walter Diaz" last="Neira">Walter Diaz Neira</name><affiliation><mods:affiliation>Department of Neurology, Fundación Jimenez Díaz, Madrid, Spain</mods:affiliation></affiliation></author><author><name sortKey="Sanchez, Vicenta" sort="Sanchez, Vicenta" uniqKey="Sanchez V" first="Vicenta" last="Sanchez">Vicenta Sanchez</name><affiliation><mods:affiliation>Department of Neurology, Fundación Jimenez Díaz, Madrid, Spain</mods:affiliation></affiliation></author><author><name sortKey="Mena, Maria Angeles" sort="Mena, Maria Angeles" uniqKey="Mena M" first="Maria Angeles" last="Mena">Maria Angeles Mena</name><affiliation><mods:affiliation>Monoamine Research Laboratory, Centro Ramón y Cajal, Madrid, Spain</mods:affiliation></affiliation></author><author><name sortKey="De Yebenes" sort="De Yebenes" uniqKey="De Yebenes" last="De Yebenes">de Yebenes</name><affiliation><mods:affiliation>Department of Neurology, Fundación Jimenez Díaz, Madrid, Spain</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:58E04CD2695E5BBF9B482C9A1EFF6425DAAB4730</idno><date when="1995" year="1995">1995</date><idno type="doi">10.1002/mds.870100111</idno><idno type="url">https://api.istex.fr/document/58E04CD2695E5BBF9B482C9A1EFF6425DAAB4730/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001D99</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">The effects of cisapride on plasma L‐dopa levels and clinical response in Parkinson's disease</title><author><name sortKey="Neira, Walter Diaz" sort="Neira, Walter Diaz" uniqKey="Neira W" first="Walter Diaz" last="Neira">Walter Diaz Neira</name><affiliation><mods:affiliation>Department of Neurology, Fundación Jimenez Díaz, Madrid, Spain</mods:affiliation></affiliation></author><author><name sortKey="Sanchez, Vicenta" sort="Sanchez, Vicenta" uniqKey="Sanchez V" first="Vicenta" last="Sanchez">Vicenta Sanchez</name><affiliation><mods:affiliation>Department of Neurology, Fundación Jimenez Díaz, Madrid, Spain</mods:affiliation></affiliation></author><author><name sortKey="Mena, Maria Angeles" sort="Mena, Maria Angeles" uniqKey="Mena M" first="Maria Angeles" last="Mena">Maria Angeles Mena</name><affiliation><mods:affiliation>Monoamine Research Laboratory, Centro Ramón y Cajal, Madrid, Spain</mods:affiliation></affiliation></author><author><name sortKey="De Yebenes" sort="De Yebenes" uniqKey="De Yebenes" last="De Yebenes">de Yebenes</name><affiliation><mods:affiliation>Department of Neurology, Fundación Jimenez Díaz, Madrid, Spain</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1995-01">1995-01</date><biblScope unit="vol">10</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="66">66</biblScope><biblScope unit="page" to="70">70</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">58E04CD2695E5BBF9B482C9A1EFF6425DAAB4730</idno><idno type="DOI">10.1002/mds.870100111</idno><idno type="ArticleID">MDS870100111</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cisapride</term><term>L‐Dopa</term><term>Parkinson's disease</term><term>Pharmacokinetics</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Cisapride (CIS) is a prokinetic agent that increases gastrointestinal motility in normal individuals and improves constipation in Parkinson's disease (PD). We studied the effects of CIS on the clinical response and the peripheral pharmacokinetics of orally administered L‐dopa given to patients with PD. Twenty patients with idiopathic PD and chronic constipation, whose response to L‐dopa was suboptimal or characterized by fluctuations, agreed to participate in an open study that lasted for 2 weeks. Fourteen patients completed the study (mean age 65 ± 9.3 years, mean duration of treatment 5.7 ± 4.2 years, mean L‐dopa daily doses 658.9 ± 269.9 mg); six patients were excluded due to lack of compliance or changes in medication during the study. The end points of the study included the mean levels of L‐dopa, the height of the peak of L‐dopa in plasma, mean plasma levels of 3‐OM‐dopa, and the speed and quality of gait and visuomanual corrdination before and during treatment with CIS. CIS increased peak plasma levels of L‐dopa by 37% and the mean plasma levels of L‐dopa by 13% with respect to those obtained with the same dose of L‐dopa before the addition of CIS. Therefor, CIS appears to increase early absorption of L‐dopa through acceleration of gastric emptying. CIS also increased plasma 3‐OM‐dopa levels, improved visuomanual coordination, and reduced gait disability. CIS improves gastrointestinal function and response to L‐dopa in patients with PD and could be a helpful add‐on medication in these patients.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Walter Diaz Neira</name><affiliations><json:string>Department of Neurology, Fundación Jimenez Díaz, Madrid, Spain</json:string></affiliations></json:item><json:item><name>Vicenta Sanchez</name><affiliations><json:string>Department of Neurology, Fundación Jimenez Díaz, Madrid, Spain</json:string></affiliations></json:item><json:item><name>Maria Angeles Mena</name><affiliations><json:string>Monoamine Research Laboratory, Centro Ramón y Cajal, Madrid, Spain</json:string></affiliations></json:item><json:item><name>Dr. de Yebenes</name><affiliations><json:string>Department of Neurology, Fundación Jimenez Díaz, Madrid, Spain</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Cisapride</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>L‐Dopa</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Pharmacokinetics</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item></subject><language><json:string>eng</json:string></language><abstract>Cisapride (CIS) is a prokinetic agent that increases gastrointestinal motility in normal individuals and improves constipation in Parkinson's disease (PD). We studied the effects of CIS on the clinical response and the peripheral pharmacokinetics of orally administered L‐dopa given to patients with PD. Twenty patients with idiopathic PD and chronic constipation, whose response to L‐dopa was suboptimal or characterized by fluctuations, agreed to participate in an open study that lasted for 2 weeks. Fourteen patients completed the study (mean age 65 ± 9.3 years, mean duration of treatment 5.7 ± 4.2 years, mean L‐dopa daily doses 658.9 ± 269.9 mg); six patients were excluded due to lack of compliance or changes in medication during the study. The end points of the study included the mean levels of L‐dopa, the height of the peak of L‐dopa in plasma, mean plasma levels of 3‐OM‐dopa, and the speed and quality of gait and visuomanual corrdination before and during treatment with CIS. CIS increased peak plasma levels of L‐dopa by 37% and the mean plasma levels of L‐dopa by 13% with respect to those obtained with the same dose of L‐dopa before the addition of CIS. Therefor, CIS appears to increase early absorption of L‐dopa through acceleration of gastric emptying. CIS also increased plasma 3‐OM‐dopa levels, improved visuomanual coordination, and reduced gait disability. CIS improves gastrointestinal function and response to L‐dopa in patients with PD and could be a helpful add‐on medication in these patients.</abstract><qualityIndicators><score>5.473</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 792 pts (letter)</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1526</abstractCharCount><pdfWordCount>2581</pdfWordCount><pdfCharCount>16194</pdfCharCount><pdfPageCount>5</pdfPageCount><abstractWordCount>241</abstractWordCount></qualityIndicators><title>The effects of cisapride on plasma L‐dopa levels and clinical response in Parkinson's disease</title><genre><json:string>Serial article</json:string></genre><host><volume>10</volume><pages><total>5</total><last>70</last><first>66</first></pages><issn><json:string>0885-3185</json:string></issn><issue>1</issue><subject><json:item><value>Article</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>1995</publicationDate><copyrightDate>1995</copyrightDate><doi><json:string>10.1002/mds.870100111</json:string></doi><id>58E04CD2695E5BBF9B482C9A1EFF6425DAAB4730</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/58E04CD2695E5BBF9B482C9A1EFF6425DAAB4730/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/58E04CD2695E5BBF9B482C9A1EFF6425DAAB4730/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/58E04CD2695E5BBF9B482C9A1EFF6425DAAB4730/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">The effects of cisapride on plasma L‐dopa levels and clinical response in Parkinson's disease</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Wiley Subscription Services, Inc., A Wiley Company</p></availability><date>1995</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">The effects of cisapride on plasma L‐dopa levels and clinical response in Parkinson's disease</title><author><persName><forename type="first">Walter Diaz</forename><surname>Neira</surname></persName><affiliation>Department of Neurology, Fundación Jimenez Díaz, Madrid, Spain</affiliation></author><author><persName><forename type="first">Vicenta</forename><surname>Sanchez</surname></persName><affiliation>Department of Neurology, Fundación Jimenez Díaz, Madrid, Spain</affiliation></author><author><persName><forename type="first">Maria Angeles</forename><surname>Mena</surname></persName><affiliation>Monoamine Research Laboratory, Centro Ramón y Cajal, Madrid, Spain</affiliation></author><author><persName><surname>de Yebenes</surname><roleName type="degree">Dr.</roleName></persName><note type="correspondence"><p>Correspondence: Department of Neurology, Fundación Jimenez Díaz, Avda Reyes Católicos 2, Ciudad Universitaria, Madrid 28040, Spain</p></note><affiliation>Department of Neurology, Fundación Jimenez Díaz, Madrid, Spain</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1995-01"></date><biblScope unit="vol">10</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="66">66</biblScope><biblScope unit="page" to="70">70</biblScope></imprint></monogr><idno type="istex">58E04CD2695E5BBF9B482C9A1EFF6425DAAB4730</idno><idno type="DOI">10.1002/mds.870100111</idno><idno type="ArticleID">MDS870100111</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1995</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Cisapride (CIS) is a prokinetic agent that increases gastrointestinal motility in normal individuals and improves constipation in Parkinson's disease (PD). We studied the effects of CIS on the clinical response and the peripheral pharmacokinetics of orally administered L‐dopa given to patients with PD. Twenty patients with idiopathic PD and chronic constipation, whose response to L‐dopa was suboptimal or characterized by fluctuations, agreed to participate in an open study that lasted for 2 weeks. Fourteen patients completed the study (mean age 65 ± 9.3 years, mean duration of treatment 5.7 ± 4.2 years, mean L‐dopa daily doses 658.9 ± 269.9 mg); six patients were excluded due to lack of compliance or changes in medication during the study. The end points of the study included the mean levels of L‐dopa, the height of the peak of L‐dopa in plasma, mean plasma levels of 3‐OM‐dopa, and the speed and quality of gait and visuomanual corrdination before and during treatment with CIS. CIS increased peak plasma levels of L‐dopa by 37% and the mean plasma levels of L‐dopa by 13% with respect to those obtained with the same dose of L‐dopa before the addition of CIS. Therefor, CIS appears to increase early absorption of L‐dopa through acceleration of gastric emptying. CIS also increased plasma 3‐OM‐dopa levels, improved visuomanual coordination, and reduced gait disability. CIS improves gastrointestinal function and response to L‐dopa in patients with PD and could be a helpful add‐on medication in these patients.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Cisapride</term></item><item><term>L‐Dopa</term></item><item><term>Pharmacokinetics</term></item><item><term>Parkinson's disease</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1994-07-28">Registration</change><change when="1995-01">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/58E04CD2695E5BBF9B482C9A1EFF6425DAAB4730/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="subtitle">Official Journal of the Movement Disorder Society</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="10"><doi origin="wiley" registered="yes">10.1002/mds.v10:1</doi><numberingGroup><numbering type="journalVolume" number="10">10</numbering><numbering type="journalIssue">1</numbering></numberingGroup><coverDate startDate="1995-01">January 1995</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="11" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.870100111</doi><idGroup><id type="unit" value="MDS870100111"></id></idGroup><countGroup><count type="pageTotal" number="5"></count></countGroup><titleGroup><title type="articleCategory">Article</title><title type="tocHeading1">Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 1995 Movement Disorder Society</copyright><eventGroup><event type="manuscriptAccepted" date="1994-07-28"></event><event type="firstOnline" date="2004-10-12"></event><event type="publishedOnlineFinalForm" date="2004-10-12"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:HeaderRef result:HeaderRef" date="2010-03-09"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-11-01"></event></eventGroup><numberingGroup><numbering type="pageFirst">66</numbering><numbering type="pageLast">70</numbering></numberingGroup><correspondenceTo>Department of Neurology, Fundación Jimenez Díaz, Avda Reyes Católicos 2, Ciudad Universitaria, Madrid 28040, Spain</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS870100111.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="1"></count><count type="tableTotal" number="2"></count><count type="referenceTotal" number="29"></count></countGroup><titleGroup><title type="main" xml:lang="en">The effects of cisapride on plasma <sc>L</sc>‐dopa levels and clinical response in Parkinson's disease</title><title type="short" xml:lang="en">CISAPRIDE AND PLASMA <sc>L</sc>‐DOPA LEVELS</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Walter Diaz</givenNames><familyName>Neira</familyName></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Vicenta</givenNames><familyName>Sanchez</familyName></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Maria Angeles</givenNames><familyName>Mena</familyName></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><honorifics>Dr.</honorifics><givenNames>Justo Garcia</givenNames><familyName>de Yebenes</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="ES" type="organization"><unparsedAffiliation>Department of Neurology, Fundación Jimenez Díaz, Madrid, Spain</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="ES" type="organization"><unparsedAffiliation>Monoamine Research Laboratory, Centro Ramón y Cajal, Madrid, Spain</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Cisapride</keyword><keyword xml:id="kwd2"><sc>L</sc>‐Dopa</keyword><keyword xml:id="kwd3">Pharmacokinetics</keyword><keyword xml:id="kwd4">Parkinson's disease</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Cisapride (CIS) is a prokinetic agent that increases gastrointestinal motility in normal individuals and improves constipation in Parkinson's disease (PD). We studied the effects of CIS on the clinical response and the peripheral pharmacokinetics of orally administered <sc>L</sc>‐dopa given to patients with PD. Twenty patients with idiopathic PD and chronic constipation, whose response to <sc>L</sc>‐dopa was suboptimal or characterized by fluctuations, agreed to participate in an open study that lasted for 2 weeks. Fourteen patients completed the study (mean age 65 ± 9.3 years, mean duration of treatment 5.7 ± 4.2 years, mean <sc>L</sc>‐dopa daily doses 658.9 ± 269.9 mg); six patients were excluded due to lack of compliance or changes in medication during the study. The end points of the study included the mean levels of <sc>L</sc>‐dopa, the height of the peak of <sc>L</sc>‐dopa in plasma, mean plasma levels of 3‐OM‐dopa, and the speed and quality of gait and visuomanual corrdination before and during treatment with CIS. CIS increased peak plasma levels of <sc>L</sc>‐dopa by 37% and the mean plasma levels of <sc>L</sc>‐dopa by 13% with respect to those obtained with the same dose of <sc>L</sc>‐dopa before the addition of CIS. Therefor, CIS appears to increase early absorption of <sc>L</sc>‐dopa through acceleration of gastric emptying. CIS also increased plasma 3‐OM‐dopa levels, improved visuomanual coordination, and reduced gait disability. CIS improves gastrointestinal function and response to <sc>L</sc>‐dopa in patients with PD and could be a helpful add‐on medication in these patients.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 4-12-2015--><mods version="3.6"><titleInfo lang="en"><title>The effects of cisapride on plasma L‐dopa levels and clinical response in Parkinson's disease</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>CISAPRIDE AND PLASMA L‐DOPA LEVELS</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>The effects of cisapride on plasma</title></titleInfo><name type="personal"><namePart type="given">Walter Diaz</namePart><namePart type="family">Neira</namePart><affiliation>Department of Neurology, Fundación Jimenez Díaz, Madrid, Spain</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Vicenta</namePart><namePart type="family">Sanchez</namePart><affiliation>Department of Neurology, Fundación Jimenez Díaz, Madrid, Spain</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Maria Angeles</namePart><namePart type="family">Mena</namePart><affiliation>Monoamine Research Laboratory, Centro Ramón y Cajal, Madrid, Spain</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="termsOfAddress">Dr.</namePart><namePart type="family">de Yebenes</namePart><affiliation>Department of Neurology, Fundación Jimenez Díaz, Madrid, Spain</affiliation><description>Correspondence: Department of Neurology, Fundación Jimenez Díaz, Avda Reyes Católicos 2, Ciudad Universitaria, Madrid 28040, Spain</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">article</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">1995-01</dateIssued><dateValid encoding="w3cdtf">1994-07-28</dateValid><copyrightDate encoding="w3cdtf">1995</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">1</extent><extent unit="tables">2</extent><extent unit="references">29</extent></physicalDescription><abstract lang="en">Cisapride (CIS) is a prokinetic agent that increases gastrointestinal motility in normal individuals and improves constipation in Parkinson's disease (PD). We studied the effects of CIS on the clinical response and the peripheral pharmacokinetics of orally administered L‐dopa given to patients with PD. Twenty patients with idiopathic PD and chronic constipation, whose response to L‐dopa was suboptimal or characterized by fluctuations, agreed to participate in an open study that lasted for 2 weeks. Fourteen patients completed the study (mean age 65 ± 9.3 years, mean duration of treatment 5.7 ± 4.2 years, mean L‐dopa daily doses 658.9 ± 269.9 mg); six patients were excluded due to lack of compliance or changes in medication during the study. The end points of the study included the mean levels of L‐dopa, the height of the peak of L‐dopa in plasma, mean plasma levels of 3‐OM‐dopa, and the speed and quality of gait and visuomanual corrdination before and during treatment with CIS. CIS increased peak plasma levels of L‐dopa by 37% and the mean plasma levels of L‐dopa by 13% with respect to those obtained with the same dose of L‐dopa before the addition of CIS. Therefor, CIS appears to increase early absorption of L‐dopa through acceleration of gastric emptying. CIS also increased plasma 3‐OM‐dopa levels, improved visuomanual coordination, and reduced gait disability. CIS improves gastrointestinal function and response to L‐dopa in patients with PD and could be a helpful add‐on medication in these patients.</abstract><subject lang="en"><genre>Keywords</genre><topic>Cisapride</topic><topic>L‐Dopa</topic><topic>Pharmacokinetics</topic><topic>Parkinson's disease</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title><subTitle>Official Journal of the Movement Disorder Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>1995</date><detail type="volume"><caption>vol.</caption><number>10</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>66</start><end>70</end><total>5</total></extent></part></relatedItem><identifier type="istex">58E04CD2695E5BBF9B482C9A1EFF6425DAAB4730</identifier><identifier type="DOI">10.1002/mds.870100111</identifier><identifier type="ArticleID">MDS870100111</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 1995 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001D99 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001D99 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:58E04CD2695E5BBF9B482C9A1EFF6425DAAB4730
|texte= The effects of cisapride on plasma L‐dopa levels and clinical response in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |